Skip to main content
Top
Published in: International Urology and Nephrology 9/2017

01-09-2017 | Urology - Original Paper

The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy

Authors: Sacit Nuri Gorgel, Osman Kose, Esra Meltem Koc, Erhan Ates, Yigit Akin, Yuksel Yilmaz

Published in: International Urology and Nephrology | Issue 9/2017

Login to get access

Abstract

Purposes

We aimed to evaluate prognostic significance of preoperatively assessed aspartate aminotransaminase (AST)/alanine aminotransferase (ALT) (De Ritis) ratio on survival in bladder cancer (BC) patients underwent radical cystectomy (RC).

Methods

We, respectively, analysed clinical and pathological data of 153 patients who underwent RC for BC between February 2006 and December 2016 at a tertiary level hospital. The potential prognostic value of De Ritis ratio was assessed by using ROC curve analysis. The effect of the De Ritis ratio was analysed by the Kaplan–Meier method and Cox regression hazard models for patients’ disease-specific survival (DSS) and overall survival (OAS).

Results

We had 149 BC patients, in total. Mean age was 61.65 ± 9.13 years. One hundred and thirty-nine (93.3%) of the patients were men. According to ROC analysis, optimal threshold of De Ritis ratio for DSS was 1.30. In Kaplan–Meier analyses, the high De Ritis ratio group showed worse progression in DSS and OAS (all parameters, p < 0.001). On Cox regression models of clinical and pathological parameters to predict DSS, De Ritis ratio (HR 5.79, 95% CI 2.25–15.13), pathological T stage (HR 15.89, 95% CI 3.92–64.33, in all p < 0.001); and to predict OAS, De Ritis ratio (HR 2.61, 95% CI 1.49–4.56; p < 0.001), pathological T stage (HR 5.42, 95% CI 2.63–11.64; p < 0.001) and age (HR 1.05, 95% CI 1.02–1.08; p = 0.001) were determined as independent prognostic factors.

Conclusions

Preoperative elevated De Ritis ratio could be an independent prognostic factor in BC patients underwent RC. Our results should be confirmed by large and properly designed prospective, randomized trials.
Literature
1.
go back to reference May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, Hakenberg OW, PROMETRICS 2011 Research Group (2017) Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. Int Urol Nephrol 49:247–254CrossRefPubMed May M, Protzel C, Vetterlein MW, Gierth M, Noldus J, Karl A, Grimm T, Wullich B, Grimm MO, Nuhn P, Bastian PJ, Roigas J, Hadaschik B, Gilfrich C, Burger M, Fisch M, Brookman-May S, Aziz A, Hakenberg OW, PROMETRICS 2011 Research Group (2017) Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database. Int Urol Nephrol 49:247–254CrossRefPubMed
2.
go back to reference Chang IW, Lin VC, Wu WJ, Liang PI, Li WM, Yeh BW, He HL, Liao AC, Chan TC, Li CF (2016) Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. J Cancer 7:1396–1405CrossRefPubMedPubMedCentral Chang IW, Lin VC, Wu WJ, Liang PI, Li WM, Yeh BW, He HL, Liao AC, Chan TC, Li CF (2016) Complement component 1, s subcomponent overexpression is an independent poor prognostic indicator in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. J Cancer 7:1396–1405CrossRefPubMedPubMedCentral
3.
go back to reference Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241CrossRefPubMed Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241CrossRefPubMed
4.
go back to reference Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675CrossRefPubMed Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19:666–675CrossRefPubMed
5.
go back to reference World Health Organization (WHO) Consensus Conference on Bladder Cancer, Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, Mills RD, Montie JD, Sagalowsky AI, Stein JP, Stenzl A, Studer UE, Volkmer BG (2007) Urinary diversion. Urology 69(1 Suppl):17–49 World Health Organization (WHO) Consensus Conference on Bladder Cancer, Hautmann RE, Abol-Enein H, Hafez K, Haro I, Mansson W, Mills RD, Montie JD, Sagalowsky AI, Stein JP, Stenzl A, Studer UE, Volkmer BG (2007) Urinary diversion. Urology 69(1 Suppl):17–49
6.
go back to reference Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette–Guérin. Eur Urol 62:118–125CrossRefPubMed Palou J, Sylvester RJ, Faba OR, Parada R, Peña JA, Algaba F, Villavicencio H (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette–Guérin. Eur Urol 62:118–125CrossRefPubMed
7.
go back to reference Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245:194–205CrossRefPubMed Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245:194–205CrossRefPubMed
9.
go back to reference Rawson NS, Peto J (1990) An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 61:597–604CrossRefPubMedPubMedCentral Rawson NS, Peto J (1990) An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer 61:597–604CrossRefPubMedPubMedCentral
10.
go back to reference Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N (2008) Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer 99:883–893CrossRefPubMedPubMedCentral Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N (2008) Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer 99:883–893CrossRefPubMedPubMedCentral
11.
go back to reference Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM (2010) Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 133:788–795CrossRefPubMed Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM (2010) Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol 133:788–795CrossRefPubMed
12.
14.
go back to reference Tan X, Xiao K, Liu W, Zhang T, Tang H (2013) Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology 60:1892–1895PubMed Tan X, Xiao K, Liu W, Zhang T, Tang H (2013) Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases. Hepatogastroenterology 60:1892–1895PubMed
15.
go back to reference Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M (2015) The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol 194:30–35CrossRefPubMed Bezan A, Mrsic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M (2015) The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. J Urol 194:30–35CrossRefPubMed
16.
go back to reference Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K (2017) Evaluation of preoperative aspartate transaminase/alanine transaminase ratio as an independent predictive biomarker in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy: a propensity score matching study. Clin Genitourin Cancer. doi:10.1016/j.clgc.2017.04.011 Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K (2017) Evaluation of preoperative aspartate transaminase/alanine transaminase ratio as an independent predictive biomarker in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy: a propensity score matching study. Clin Genitourin Cancer. doi:10.​1016/​j.​clgc.​2017.​04.​011
17.
go back to reference Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK (2017) De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int 119:261–267CrossRefPubMed Lee H, Lee SE, Byun SS, Kim HH, Kwak C, Hong SK (2017) De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study. BJU Int 119:261–267CrossRefPubMed
18.
go back to reference Lee H, Choi YH, Sung HH, Han DH, Jeon HG, Chang Jeong B, Seo SI, Jeon SS, Lee HM, Choi HY (2017) De Ritis ratio (AST/ALT) as a significant prognostic factor in patients with upper tract urothelial cancer treated with surgery. Clin Genitourin Cancer 15:e379–e385CrossRefPubMed Lee H, Choi YH, Sung HH, Han DH, Jeon HG, Chang Jeong B, Seo SI, Jeon SS, Lee HM, Choi HY (2017) De Ritis ratio (AST/ALT) as a significant prognostic factor in patients with upper tract urothelial cancer treated with surgery. Clin Genitourin Cancer 15:e379–e385CrossRefPubMed
19.
go back to reference Cho YH, Hwang JE, Chung HS, Kim MS, Hwang EC, Jung SI, Kang TW, Kwon DD, Choi SH, Kim HT, Kim TH, Kwon TG, Noh JH, Kim MK, Kim CS, Kang SG, Kang SH, Cheon J, Lee CH, Ku JY, Ha HK, Tae BS, Jeong CW, Ku JH, Kwak C, Kim HH (2017) The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma. Int Urol Nephrol. doi:10.1007/s11255-017-1613-z Cho YH, Hwang JE, Chung HS, Kim MS, Hwang EC, Jung SI, Kang TW, Kwon DD, Choi SH, Kim HT, Kim TH, Kwon TG, Noh JH, Kim MK, Kim CS, Kang SG, Kang SH, Cheon J, Lee CH, Ku JY, Ha HK, Tae BS, Jeong CW, Ku JH, Kwak C, Kim HH (2017) The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma. Int Urol Nephrol. doi:10.​1007/​s11255-017-1613-z
20.
go back to reference Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270PubMed Warburg O (1956) On respiratory impairment in cancer cells. Science 124:269–270PubMed
21.
go back to reference Walker-Samuel S, Ramasawmy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP, Richardson S, Gonçalves M, Parkes HG, Arstad E, Thomas DL, Pedley RB, Lythgoe MF, Golay X (2013) In vivo imaging of glucose uptake and metabolism in tumors. Nat Med 19:1067–1072CrossRefPubMedPubMedCentral Walker-Samuel S, Ramasawmy R, Torrealdea F, Rega M, Rajkumar V, Johnson SP, Richardson S, Gonçalves M, Parkes HG, Arstad E, Thomas DL, Pedley RB, Lythgoe MF, Golay X (2013) In vivo imaging of glucose uptake and metabolism in tumors. Nat Med 19:1067–1072CrossRefPubMedPubMedCentral
22.
go back to reference Dorward A, Sweet S, Moorehead R, Singh G (1997) Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. J Bioenerg Biomembr 29:385–392CrossRefPubMed Dorward A, Sweet S, Moorehead R, Singh G (1997) Mitochondrial contributions to cancer cell physiology: redox balance, cell cycle, and drug resistance. J Bioenerg Biomembr 29:385–392CrossRefPubMed
23.
go back to reference Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434CrossRefPubMed Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434CrossRefPubMed
24.
go back to reference Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRefPubMedPubMedCentral Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRefPubMedPubMedCentral
25.
go back to reference DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345–19350CrossRefPubMedPubMedCentral DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345–19350CrossRefPubMedPubMedCentral
26.
go back to reference Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ (2009) Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69:7986–7993CrossRefPubMedPubMedCentral Yang C, Sudderth J, Dang T, Bachoo RM, McDonald JG, DeBerardinis RJ (2009) Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 69:7986–7993CrossRefPubMedPubMedCentral
27.
28.
go back to reference Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72:424–430CrossRefPubMed Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72:424–430CrossRefPubMed
29.
go back to reference Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95CrossRefPubMed Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11:85–95CrossRefPubMed
30.
go back to reference Tai YS, Chen CH, Huang CY, Tai HC, Wang SM, Pu YS (2015) Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev 31:307–314CrossRefPubMed Tai YS, Chen CH, Huang CY, Tai HC, Wang SM, Pu YS (2015) Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma. Diabetes Metab Res Rev 31:307–314CrossRefPubMed
31.
go back to reference ChangSG LeeJH, HongDH LeeHL, ChaiSE HoffmanRM (1994) Comparison of glucose consumption and thymidine incorporation end points on histocultured human superficial bladder tumors. Anticancer Res 14:77–83 ChangSG LeeJH, HongDH LeeHL, ChaiSE HoffmanRM (1994) Comparison of glucose consumption and thymidine incorporation end points on histocultured human superficial bladder tumors. Anticancer Res 14:77–83
32.
go back to reference Whyard T, Waltzer WC, Waltzer D, Romanov V (2016) Metabolic alterations in bladder cancer: applications for cancer imaging. Exp Cell Res 341:77–83CrossRefPubMed Whyard T, Waltzer WC, Waltzer D, Romanov V (2016) Metabolic alterations in bladder cancer: applications for cancer imaging. Exp Cell Res 341:77–83CrossRefPubMed
Metadata
Title
The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy
Authors
Sacit Nuri Gorgel
Osman Kose
Esra Meltem Koc
Erhan Ates
Yigit Akin
Yuksel Yilmaz
Publication date
01-09-2017
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 9/2017
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1648-1

Other articles of this Issue 9/2017

International Urology and Nephrology 9/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.